BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24515577)

  • 1. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
    Lin TC; Yang CY; Kao Yang YH; Lin SJ
    Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
    Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
    Chiu WY; Chien JY; Yang WS; Juang JM; Lee JJ; Tsai KS
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2729-35. PubMed ID: 24758181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
    Chiu WY; Yang WS; Chien JY; Lee JJ; Tsai KS
    PLoS One; 2018; 13(4):e0196419. PubMed ID: 29694412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
    Eiken PA; Prieto-Alhambra D; Eastell R; Abrahamsen B
    Osteoporos Int; 2017 Oct; 28(10):2921-2928. PubMed ID: 28664276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
    Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
    J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
    Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G;
    Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.
    Tanaka S; Yamamoto T; Oda E; Nakamura M; Fujiwara S
    J Bone Miner Metab; 2018 Jan; 36(1):87-94. PubMed ID: 28028633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
    Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
    Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
    Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
    Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
    Taguchi A; Tanaka S; Ozaki T; Arai K; Mori S; Ohta H; Hagino H; Tanaka S; Shiraki M; Nakamura T; Soen S;
    J Bone Miner Metab; 2023 Nov; 41(6):854-864. PubMed ID: 37897672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the jaw in a patient on raloxifene: a case report.
    Baur DA; Altay MA; Teich S; Schmitt Oswald M; Quereshy FA
    Quintessence Int; 2015 May; 46(5):423-8. PubMed ID: 25328920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.
    Kwon JW; Park EJ; Jung SY; Sohn HS; Ryu H; Suh HS
    J Dent Res; 2015 Sep; 94(9 Suppl):212S-9S. PubMed ID: 26001708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland.
    Sammut S; Malden N; Lopes V; Ralston S
    Br J Oral Maxillofac Surg; 2016 Jun; 54(5):501-5. PubMed ID: 26975575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges.
    Solomon DH; Mercer E; Woo SB; Avorn J; Schneeweiss S; Treister N
    Osteoporos Int; 2013 Jan; 24(1):237-44. PubMed ID: 22707065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
    Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
    J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.